Finance entity
All 2 tracked stories fall under one category: markets. Of the tracked stories, 1 of 2 also mention Ben Bradford, the most common co-covered peer. Across a 166-day span, the pace is roughly 0.1 stories per week. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline.
Last mentioned: Mar 13, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: markets. Of the tracked stories, 1 of 2 also mention Ben Bradford, the most common co-covered peer. Across a 166-day span, the pace is roughly 0.1 stories per week. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline. Their average consequence score of 5.5 runs below the beat's 6.2 for that window. We currently track 2 Finance stories that mention XBI, published between March 13, 2026 and August 25, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 2792 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering XBI. Shared-story counts are live from our verified record — not editorial picks.
Investors see a bifurcated biotech recovery: hot IPOs and $79 billion in China-discovered licensing deals mask shrinking seed-stage venture funding. MassBio's 2026 report highlights how venture capital is concentrating in later-stage, less risky assets.
Source: biopharmadive.com · BioPharma Dive
Josh Brown argues that biotech growth stocks are uniquely positioned to withstand the disruption risks currently de-rating the software and services sectors. By leveraging AI to accelerate discovery while maintaining regulatory and patent moats, the sector offers a rare combination of high growth and structural stability.
XBI is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
